CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 459 enrolled
Drug / intervention
OPC-34712 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01451164
NCT01451164Phase 3Completed
CompareCT.gov

A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia

Otsuka Pharmaceutical Co., Ltd.·interventional·Posted Oct 13, 2011·Updated Oct 3, 2019

In Brief

A Phase 3 clinical trial evaluating OPC-34712 and Placebo for Schizophrenia. Completed, enrolled 459 participants across 1 site.

Detailed Summary

To investigate the efficacy and safety of OPC-34712 in comparison with placebo in patients with schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 13, 2011
Enrollment StartOct 1, 2011
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 14.7 years ago

Interventions

OPC-34712drug

orally administered once daily

OPC-34712drug

orally administered once daily

OPC-34712drug

orally administered once daily

Placebodrug

orally administered once daily